GLAND Gland Pharma Q2 FY26 results (Jul–Sep 2025) and concall
Gland Pharma delivered a steady Q2 FY26 with 6% revenue growth, characterized by strong performance in the US base business and narrowing losses at Cenexi. While the first half saw 7% growth, management is highly optimistic about a 'stronger second half' driven by key launches like Dalbavancin and new CDMO contracts. The company is aggressively pivoting toward complex injectables and biologics, with significant capacity expansions underway for GLP-1 and biosimilar fill-finish.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 1.0%, net profit up 7.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 1,063 | 1,011 | 1,030 | 1,039 | 1,074 +1% |
| EBITDA | 364 | 391 | 394 | 359 | 375 +3% |
| Net profit | 282 | 295 | 290 | 269 | 302 +7% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
